[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

Ryuichi Harada, Nobuyuki Okamura, Shozo Furumoto, Katsutoshi Furukawa, Aiko Ishiki, Naoki Tomita, Kotaro Hiraoka, Shoichi Watanuki, Miho Shidahara, Masayasu Miyake, Yoichi Ishikawa, Rin Matsuda, Akie Inami, Takeo Yoshikawa, Tetsuro Tago, Yoshihito Funaki, Ren Iwata, Manabu Tashiro, Kazuhiko Yanai, Hiroyuki AraiYukitsuka Kudo

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: Visualization of the spatial distribution of neurofibrillary tangles would help in the diagnosis, prevention and treatment of dementia. The purpose of the study was to evaluate the clinical utility of [18F]THK-5117 as a highly selective tau imaging radiotracer. Methods: We initially evaluated in vitro binding of [3H]THK-5117 in post-mortem brain tissues from patients with Alzheimer’s disease (AD). In clinical PET studies, [18F]THK-5117 retention in eight patients with AD was compared with that in six healthy elderly controls. Ten subjects underwent an additional [11C]PiB PET scan within 2 weeks. Results: In post-mortem brain samples, THK-5117 bound selectively to neurofibrillary deposits, which differed from the binding target of PiB. In clinical PET studies, [18F]THK-5117 binding in the temporal lobe clearly distinguished patients with AD from healthy elderly subjects. Compared with [11C]PiB, [18F]THK-5117 retention was higher in the medial temporal cortex. Conclusion: These findings suggest that [18F]THK-5117 provides regional information on neurofibrillary pathology in living subjects.

Original languageEnglish
Pages (from-to)1052-1061
Number of pages10
JournalEuropean journal of nuclear medicine and molecular imaging
Volume42
Issue number7
DOIs
Publication statusPublished - 2015 Jun 1

Keywords

  • Alzheimer’s disease
  • Imaging
  • Neurofibrillary tangles
  • PET
  • Tau
  • [F]THK-5117

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of '[<sup>18</sup>F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease'. Together they form a unique fingerprint.

  • Cite this